(All fields required)
Please enter a valid email.
Please enter your name.
The Genetic Pharmacology Service (GPS) team at Cincinnati Children's Hospital Medical Center is comprised of specialists in molecular genetics, neurology and pharmacology research.
Tracy A. Glauser, MD Associate Director, Cincinnati Children's Research Foundation 513-636-4222 firstname.lastname@example.org
Associate Director, Cincinnati Children's Research Foundation
Director, Comprehensive Epilepsy Center
Co-Director, Genetic Pharmacology Service
Professor, UC Department of Pediatrics
Epilepsy; pharmacogenetics; clinical pharmacology
Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2010 Nov 18. doi: 10.1111/j.1528-1167.2010.02789.x.
Modi AC, Monahan S, Daniels D, Glauser TA. Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire. Epilepsy Behav. 2010 May;18(1-2):94-9
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.
Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53.
Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29.
Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94.
Modi AC, King AS, Monahan SR, Koumoutsos JE, Morita DA, Glauser TA. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia. 2009 Sep;50(9):2110-6.
Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology. 2009 Sep 1;73(9):658-64.
Glauser TA, Sankar R; Co-chairs of the Leadership in Epilepsy, Advocacy, and Development Faculty. Core elements of epilepsy diagnosis and management: expert consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty. Curr Med Res Opin. 2008 Dec;24(12):3463-77.
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8.
Alexander A. Vinks, PharmD, PhD, FCP Director, Division of Clinical Pharmacology 513-636-0159 email@example.com
Director, Division of Clinical Pharmacology
Adjunct Professor of Pharmacology
Dr. Vinks received his MS in pharmacology from the University of Toronto, Canada and a pharmacy degree and PhD in pharmacology from Leiden University, The Netherlands. He was trained as a hospital pharmacist (PharmD) and clinical pharmacologist at The Hague Hospitals Central Pharmacy, The Hague, The Netherlands.
Before joining the Division of Pharmacology Research at Cincinnati Children's Hospital Medical Center, he was director of the Clinical Pharmacology & Toxicology Laboratory at The Hague. Dr. Vinks has spent over 20 years in the field of therapeutic drug monitoring and applied pharmacokinetics, both in the research aspects of population pharmacokinetic studies, as well as in the clinical application of these approaches to clinical patient care.
Dr. Vinks holds an academic appointment with the University of Cincinnati College of Medicine and is the principal investigator for the Pediatric Pharmacology Research Unit (PPRU). He is director of the Laboratory of Applied Pharmacokinetics and Therapeutic Drug Management (LAP/TDM) and clinical pharmacology fellowship program at Cincinnati Children's. His current research interests include pharmacokinetic-pharmacodynamic (PK-PD) modeling and the application of population and simulation methods in TDM and clinical trial design. He has authored over 50 publications in the area of TDM, pharmacokinetics and clinical pharmacology. Dr. Vinks has been actively involved with International Association of Therapeutic Drug Monitoring and Clinical Toxicology from the beginning. He is chair of the TDM cost-effectiveness committee, serves as secretary of the Executive Board of Directors, and is on the editorial board of the journal Therapeutic Drug Monitoring. Dr. Vinks is both board certified in clinical pharmacology and toxicology and is a fellow of the American College of Clinical Pharmacology.
Certification American Board of Clinical Pharmacology, 2001.
PhD Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.
PharmD Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986 .
MS Pharmacology, University of Toronto, Toronto Canada, 1983.
MS Pharmacy, Leiden University, Leiden, The Netherlands, 1982.
Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24. Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI. Pharmacokinetics and pharmacodynamics of mycophenolic Acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2011 Feb;40(4):307-13. Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62. Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2010 Apr 23. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.
Vargus-Adams JN, McMahon MA, Michaud LJ, Bean J, Vinks AA. Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. PM R. 2010 Jan;2(1):37-42. Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29. Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94. Prausa SE, Fukuda T, Maseck D, Curtsinger KL, Liu C, Zhang K, Nick TG, Sherbotie JR, Ellis EN, Goebel J, Vinks AA. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009 May;85(5):495-500. Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008 May-Jun;22(3):281-91.
Kejian Zhang, MD, MBA Director, Molecular Genetics Laboratory 513-636-0121 firstname.lastname@example.org
Director, Molecular Genetics Laboratory
Associate Professor, UC Department of Pediatrics
Molecular genetics diagnosis of inherited immunodeficiency disorders and other genetic conditions
MD: Tianjin Medical University, Tianjin, China, 1993
MBA: University of Cincinnati, College of Business Administration, 2001
Residency: Gong'an Hospital, Tianjin, China, 1993-1995
Fellowship: Clinical Molecular Genetics Fellow, Division of Human Genetics, Cincinnati Children's Hospital, 2002-2004
Zhang K, Jordan MB, Klein P, Villanueva J, Risma K, Filipovic AH. .Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial hemophagocytic lymphohistiocytosis. Blood. 2011 August 31.
Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood. 2010 Nov 4;116(18):3398-408.
Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010 Aug 19;116(7):1079-82.
Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010 Jul 15;55(1):134-40. Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29. Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94. Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol. 2009 Jul;132(1):116-23. Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009 Sep;76(5):334-44. Prausa SE, Fukuda T, Maseck D, Curtsinger KL, Liu C, Zhang K, Nick TG, Sherbotie JR, Ellis EN, Goebel J, Vinks AA. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009 May;85(5):495-500. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008 Sep;58(9):2892-6.
Peggy O. Clark, MSN, APRN, PNP Pediatric Nurse Practitioner, Division of Neurology 513-636-8467 email@example.com
Pediatric Nurse Practitioner, Division of Neurology
Peggy Clark received her undergraduate nursing degree from the University of Kentucky. She graduated with honors from the university’s Honors Program, served as student senator for the College of Nursing, and was named Outstanding Nursing Student in her senior year. She has worked at Cincinnati Children’s Hospital Medical Center since receiving her undergraduate nursing degree, and has been a clinical nurse, assistant head nurse, educational nurse specialist, and a nurse practitioner with an epilepsy research focus since 1995. She is a member of the Children’s Medical Center Federal Credit Union Board of Directors, The Greater Cincinnati Epilepsy Foundation Board of Directors, and the APN Professional Inquiry Council.
Cynthia A. Prows, MSN, CNS
Genetics Clinical Nurse Specialist, Division of Human Genetics 513-636-7963 firstname.lastname@example.org
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2014 Cincinnati Children's Hospital Medical Center